Medicalgorithmics is pleased to announce that its subsidiary, Kardiolytics, has been granted a new patent in the United States for a method of numerical modeling of blood flow in arteries. This patented method is a crucial component of the VCAST technology, which facilitates non-invasive diagnostics of coronary artery disease.
The patent, numbered US20240120110A1, was issued in early April. It details a method for modeling arterial blood flow that allows for the analysis of atherosclerotic plaque surface deformation and the stress acting upon it. This innovation is instrumental in the VCAST technology developed by Kardiolytics, which aims to enhance the diagnosis and treatment of heart disease, particularly by assessing the risk of plaque rupture or erosion.
“This new patent underscores the medical and commercial potential of the VCAST technology. It highlights our innovation and strengthens the competitive edge and protection of our technology. Additionally, it will positively impact the regulatory approval processes in both the EU and the USA, which are essential for the commercial deployment of our technology,” said Przemysław Tadla, Board Member for Technology and COO at Kardiolytics. “VCAST offers a non-invasive, hospitalization-free diagnostic solution for coronary artery disease, accelerating and improving the diagnostic and treatment processes for patients through AI-assisted analysis of CT scans.”
In the fourth quarter of 2023, Kardiolytics initiated the CE certification process for the VCAST technology in the European Union market. Following certification, the company plans to start commercialization in Europe and will apply for FDA approval in the US under the 510(k) clearance procedure. Commercialization of VCAST in the US is targeted for 2025.
Last year, Medicalgorithmics announced two other US patents related to the VCAST technology. In January 2023, Kardiolytics received a patent (US 11521322B2) for machine learning-based segmentation of coronary vessels in contrast-enhanced CT images. Another patent, granted in April 2023, covers an autonomous method for modeling blood vessels using medical imaging data. Additionally, Kardiolytics has filed several other patent applications in the US concerning innovative elements of the VCAST technology, which are currently under review. These patents and applications confirm the innovation of the VCAST technology, strengthen its competitive protection, and increase its market value.
* End *